In the face of fast-changing global public health threats, there is an urgent demand for novel detection platforms that combine high sensitivity with robust selectivity in real samples. Electrochemiluminescence (ECL), as a powerful analytical tool, offers excellent sensitivity and low background for biosensing. However, its reliance on traditional recognition elements limits the specificity and further applications in trace-level target detection. The emergence of CRISPR/Cas systems, with their programmable recognition and powerful signal amplification via nonspecific trans-cleavage activity, presents a transformative opportunity. In this review, we focus on the development of CRISPR/Cas-powered ECL biosensing platforms for overcoming these challenges. We first introduce the fundamental mechanisms and main integration strategies that couple the precise nucleic acid recognition and collateral cleavage of CRISPR/Cas with the sensitive light emission of ECL transduction. Subsequently, we systematically highlight the broad applicability of these hybrid platforms for detecting diverse targets, including pathogenic nucleic acids and small molecules, with direct relevance to disease diagnostics, environmental monitoring, and food safety. Finally, we discuss the current challenges and future prospects of these platforms, emphasizing their potential as next-generation tools for field-deployable, ultra-sensitive analysis in public health security.
Yang et al. (Sun,) studied this question.